KIRLOSENG’s topline growth is structurally tied to HHP/infrastructure demand and export diversification, while margins hinge on execution of high-margin segments (HHP, Defence, Fluid Dynamics) and commodity management—model 13–15% EBITDA as base, with 200 bps sensitivity to order delays or share shifts.
📊 Base Case (50% Probability)
HHP scales as guided (25%+ YoY growth), with NPCIL orders executed on time and data centre traction. LHP stabilizes (incentives offset share loss), and MENA/Africa exports grow 15–20%. Capex absorption aligns with demand; Arka’s retail book expands without material NPA spikes. Topline: 15–18% CAGR; EBITDA margins expand to 13–14% by FY28.
Continue reading “KIRLOSENG – Q3 FY26 Earnings Call – 12-Feb-26”Topline growth hinges on GLP-1/biosimilar launch execution and insulin capacity scaling, while margins and cash flow depend on Syngene’s CRDMO recovery and debt reduction pace—model 12–18% revenue CAGR with 25–28% EBITDA as base, but skew risks to downside on regulatory delays.
📊 Base Case (50% Probability)
Liraglutide/semaglutide launch in EU/Canada by late 2026; insulin capacity doubles on schedule, capturing 15–20% market share in interchangeable segments. Biosimilars grow 15–18% YoY (new launches offset legacy erosion); generics sustain 20%+ growth. Trigger: Regulatory clarity + successful tech transfers. Outcome: Group revenue grows 12–15% YoY; EBITDA margins expand to 26–28%.
Continue reading “BIOCON – Q3 FY26 Earnings Call – 13-Feb-26”BEML’s topline hinges on Rail & Metro execution (15,000-car TAM) and Defense L1 conversions, but near-term capacity and FX risks cap upside; bottomline faces 16–18-month FX headwind and capex drag; margins remain range-bound (100 bps either side) absent supply chain breakthroughs or FX tailwinds.
📊 Base Case (50% Probability)
BRITANNIA’s revenue may rise 8–10%, driven by e-commerce and adjacencies, though GST shifts and regional rivals weigh near term. Profit growth depends on commodity stability and margin discipline, with EBITDA at 19–21% if brand spend is balanced; gross margins volatile at 40–44%.
📊 Base Case (50% Probability)
Key Variables: (1) GST transition completes by Q1 FY27, (2) Commodity stability (flour/RPO ±5%).
Outcome: Revenue growth stabilizes at 8–10% (volume +5%, GST tailwinds +3–4%). Gross margins sustain at 42–44%; EBITDA margins hold at 19–21% with disciplined brand spend. Adjacencies grow at 20%+ (e-comm penetration reaches 12% by FY27). Cheese shows early turnaround signs; state incentives partially offset. Labor Code costs contained.
Topline likely to sustain 20%+ YoY growth led by paints/B2B, but bottomline hinges on B2B breakeven timing and margin expansion in chemicals/renewables; structural premiumization in paints offsets cyclical chemical pressures, while CAPEX completion unlocks free cash flow from FY27.
📊 Base Case (50% Probability)
Hindalco’s topline growth hinges on Bay Minette/Aditya Refinery execution and LME trends; bottomline volatility driven by Oswego insurance timing and hedge roll-offs; margins resilient in India (structural cost advantage) but Novelis recovery lags until FY28.
📊 Base Case (50% Probability)